摘要
目的观察噻托溴铵对慢性阻塞性肺病(COPD)患者肺功能昼夜变化节律的影响。方法 121例COPD患者,随机分为三组。Tio-AM组(n=43)每日09:00时给予噻托溴铵18μg吸入;Tio-PM组(n=38)每日21:00时给予噻托溴铵18μg吸入;对照组(n=40)予氨溴索7.5～15 mg加入氯化钠注射液20 mL超声雾化治疗,每日3次,每次20 min。疗程均为6周,检测治疗前后第一秒用力呼出容积(FEV1)和用力肺活量(FVC),并观察不良反应。结果三组间的基线指标无显著差异(P>0.05)。治疗6周后,Tio-AM组和Tio-PM组夜间(3:00-6:00)和稳态(24 h平均值)的FEV1和FVC均高于对照组,差异有显著意义(P<0.05),Tio-AM组和Tio-PM组间无显著差异(P>0.05),两组患者24 h内所有观察点FEV1均高于对照组。对照组症状加重和上感发生率均高于其他两组(P<0.05),未见严重不良反应发生。结论噻托溴铵能够持续改善COPD患者的肺功能,可降低夜间急性加重风险。
AIM To observe the effects of tiotropium bromide on the overnight change in pulmonary function in chronic obstructive pulmonary disease （COPD） . METHODS One hundred and twenty-one COPD patients were randomly divided into 3 groups. The patients in the Tio-AM group （n = 43） and Tio-PM group （n = 38） were conducted with tiotropium bromide 18 mg once daily at 9 a.m. and 9 p.m., respectively. The patients in the control group （n = 40） were received uhrasonic atomization of ambroxol （7.5 - 15 mg） and sodium chloride injection （20 mL） . Patients with stable COPD underwent pulmonary function tests every 3 hours for 24 hours at baseline and after 6 weeks of treatment. The adverse reactions were also observed. RESULTS There were no significant differences among three groups at baseline （P 〉 0.05） . After treatment, mean forced expiratory volume in one second （FEV1 over 24 hours）, nocturnal FEV （mean of FEV1 3 a.m. to 6 p.m.） and forced vital capacity （FVC） in the Tio-AM group and Tio-PM group were higher compared with those in the control group （P 〈 0.05） . There were no significant difference in mean FEV, nocturnal FEV and
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2013年第3期204-207,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
噻托溴铵
肺疾病
慢性阻塞性
呼吸功能试验
昼夜节律
tiotropium bromide
pulmonary disease, chronic obstructive
respiratory function tests
circadian rhythm
